Vaccinex, Inc. Common Stock
VCNX
VCNX: Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
moreShow VCNX Financials
Recent trades of VCNX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by VCNX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Use of semaphorin-4d binding molecules for the treatment of rett syndrome Mar. 07, 2023
-
Patent Title: Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent Feb. 07, 2023
-
Patent Title: Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability Dec. 27, 2022
-
Patent Title: Human anti-semaphorin 4d antibody Aug. 30, 2022
-
Patent Title: Anti-cd100 antibodies and methods for using the same Mar. 15, 2022
-
Patent Title: Use of semaphorin-4d inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases Aug. 03, 2021
-
Patent Title: Integral membrane protein display on poxvirus extracellular enveloped virions Dec. 22, 2020
-
Patent Title: Polynucleotides encoding anti-cxcl13 antibodies Nov. 10, 2020
-
Patent Title: Use of semaphorin-4d binding molecules for treating neurodegenerative disorders Oct. 13, 2020
-
Patent Title: Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit May. 26, 2020
-
Patent Title: Methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells May. 05, 2020
-
Patent Title: Integral membrane protein display on poxvirus extracellular enveloped virions Mar. 03, 2020
-
Patent Title: Integral membrane protein display on poxvirus extracellular enveloped virions Feb. 04, 2020
-
Patent Title: Use of anti-semaphorin-4d antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases Jan. 07, 2020
-
Patent Title: Use of semaphorin-4d binding molecules to promote neurogenesis following stroke Dec. 03, 2019
-
Patent Title: Use of semaphorin-4d binding molecules for treating neurodegenerative disorders Aug. 20, 2019
-
Patent Title: Methods of treating multiple sclerosis using anti-cd20 antibodies May. 28, 2019
-
Patent Title: Modified glycolipids and methods of making and using the same Oct. 30, 2018
-
Patent Title: Anti-cxcl13 antibodies and methods of using the same May. 08, 2018
-
Patent Title: Methods for the treatment of b cell-mediated inflammatory diseases Feb. 13, 2018
-
Patent Title: Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4d to increase tumor infiltrating leukocyte frequency Nov. 28, 2017
-
Patent Title: Targeted cd1d molecules Nov. 07, 2017
-
Patent Title: Methods for increasing immunoglobulin a levels Oct. 17, 2017
-
Patent Title: Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus Jul. 18, 2017
-
Patent Title: Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunits Jul. 11, 2017
-
Patent Title: Anti-cd100 neutralizing antibodies and methods of using the same Jun. 13, 2017
-
Patent Title: Anti-cd100 antibodies and methods of using the same Mar. 28, 2017
-
Patent Title: Modulation of nkt cell activity with antigen-loaded cd1d molecules Mar. 28, 2017
-
Patent Title: Use of semaphorin-4d binding molecules for treating neurodegenerative disorders Mar. 21, 2017
-
Patent Title: Use of semaphorin-4d binding molecules for treatment of atherosclerosis Dec. 06, 2016
-
Patent Title: Anti-cd20 antibodies and methods of use Jul. 05, 2016
-
Patent Title: Modified glycolipids and methods of making and using the same Jun. 21, 2016
-
Patent Title: Use of semaphorin-4d binding molecules for treating neurodegenerative disorders Feb. 02, 2016
-
Patent Title: Combination of sema-4d inhibitors and immunomodulators to inhibit tumors and metastases Jan. 26, 2016
-
Patent Title: Anti-sema4d antibodies and epitopes Jul. 28, 2015
-
Patent Title: Anti-vegf antibodies and uses thereof Sep. 16, 2014
-
Patent Title: Polynucleotides encoding anti-cd100 antibodies or antigen-binding fragments thereof Aug. 26, 2014
-
Patent Title: Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis Jul. 29, 2014
-
Patent Title: Anti-c35 antibody combination therapies and methods Jan. 28, 2014
-
Patent Title: Anti-cd100 neutralizing neutralizing antibodies and methods of using the same Jul. 30, 2013
-
Patent Title: Human anti-cd100 antibodies Apr. 05, 2011
-
Patent Title: Anti-il-6 monoclonal antibodies Apr. 05, 2011
-
Patent Title: Selection of human tnfα specific antibodies Oct. 05, 2010
Federal grants, loans, and purchases
Followers on VCNX's company Twitter account
Number of mentions of VCNX in WallStreetBets Daily Discussion
Recent insights relating to VCNX
Recent picks made for VCNX stock on CNBC
ETFs with the largest estimated holdings in VCNX
Flights by private jets registered to VCNX